Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
71.3 CHF | +2.00% | +12.28% | +40.08% |
Mar. 20 | Transcript : Cosmo Pharmaceuticals N.V. - Analyst/Investor Day | |
Mar. 20 | Cosmo Pharmaceuticals N.V. Proposes Dividend Payment for 2024 | CI |
Sales 2023 | 96.72M 104M 94.06M | Sales 2024 * | 233M 251M 226M | Capitalization | 1.18B 1.27B 1.14B |
---|---|---|---|---|---|
Net income 2023 | 1M 1.08M 972K | Net income 2024 * | 111M 120M 108M | EV / Sales 2023 | 9.1 x |
Net cash position 2023 * | 71.24M 76.87M 69.28M | Net cash position 2024 * | 110M 119M 107M | EV / Sales 2024 * | 4.58 x |
P/E ratio 2023 |
771
x | P/E ratio 2024 * |
10.1
x | Employees | 319 |
Yield 2023 * |
1.46% | Yield 2024 * |
2.87% | Free-Float | 44.7% |
Latest transcript on Cosmo Pharmaceuticals N.V.
1 day | +2.00% | ||
1 week | +7.22% | ||
Current month | +8.19% | ||
1 month | +7.54% | ||
3 months | +36.85% | ||
6 months | +73.48% | ||
Current year | +40.08% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 61 | 05-12-31 | |
Niall Donnelly
DFI | Director of Finance/CFO | 52 | 16-05-31 |
Chief Tech/Sci/R&D Officer | 54 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
David W Maris
BRD | Director/Board Member | 57 | 21-05-27 |
Founder | 69 | 96-12-31 | |
Director/Board Member | 64 | 05-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 10 M€ | -3.35% | - | |
0.00% | 735 M€ | -.--% | - | |
0.00% | 36 M€ | +4.92% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 71.3 | +2.00% | 28,080 |
24-03-27 | 69.9 | +7.54% | 80,766 |
24-03-26 | 65 | -2.40% | 22,291 |
24-03-25 | 66.6 | +0.76% | 18,793 |
24-03-22 | 66.1 | +4.09% | 36,057 |
Delayed Quote Swiss Exchange, March 28, 2024 at 12:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.08% | 1.24B | |
+33.46% | 701B | |
+26.24% | 571B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 319B | |
+0.74% | 210B | |
+2.95% | 210B | |
-6.05% | 201B | |
-3.61% | 157B |